Theon International PLC
THEON plans to acquire 9.8% stake in Exosens
THEON plans to acquire 9.8% stake in Exosens
PRESS RELEASE
Bloomberg (THEON:NA) / Reuters (THEON.AS)
11 October 2025 – Theon International Plc (THEON) has entered into a definitive agreement with HLD Europe SCA, Invest Prince Henri SCA and Invest Gamma Sarl, investment companies belonging to Groupe HLD (HLD), to purchase a 9.8% stake in Exosens SA (EXOSENS) for a cash consideration of €268.7 million corresponding to €54.0 per share.
EXOSENS is a leading French company specializing in advanced electro-optical technologies, including light amplification, detection and imaging systems. Following the completion of the transaction, THEON will become the second largest shareholder in EXOSENS, after Groupe HLD.
The closing of the transaction remains subject to regulatory notifications in a selected
number of countries, and is expected to take place in early Q1 2026.
In connection with the transaction, UBS Europe SE and Citibank Europe PLC have agreed to provide a bridge facility, which is intended to be refinanced with a combination of debt and newly issued equity within existing shareholders’ authorizations, to maintain a solid and flexible capital structure.
UBS Europe SE acted as sole financial advisor to THEON, while Clifford Chance provided legal advice.
Christian Hadjiminas, Founder and CEO of THEON, commented: “THEON and EXOSENS have been close commercial partners for years, having been awarded landmark contracts in Europe and Middle East. THEON remains committed to maintaining its long- standing commercial relationship with EXOSENS, which remains governed by existing contractual arrangements.”
For inquiries, please contact:
| Investor Relations Nikos Malesiotis E-Mail: ir@theon.com Tel: +30 210 6772290 | Media Contact Elli Michou E-Mail: press@theon.com Tel: +30 210 6728610 |
About THEON GROUP
THEON GROUP of companies develops and manufactures cutting-edge night vision and thermal Imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece, Cyprus, Germany, the Baltics, the United States, the Gulf States, Switzerland, Denmark, Belgium, Singapore and South Korea. THEON GROUP has more than 220,000 systems in service with Armed and Special Forces in 71 countries around the world, 26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.
www.theon.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S7.12.2025 13:50:00 CET | Press release
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
SALI7.12.2025 02:14:21 CET | Press release
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
Evaxion6.12.2025 20:00:00 CET | Press release
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
Genmab A/S6.12.2025 15:30:00 CET | Press release
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Io Therapeutics, Inc.6.12.2025 14:05:00 CET | Press release
Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human multiple myeloma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom